All of these Clinical Trials have been assembled below for reference purposes; for additional information please use our contact form or call us via 1-800-362-1479.
- Cisplatin for Chemonaive Patients
- ALIMTA Plus Gemcitabine
- Phase II trial of perioperative
- Open-Label Study of ALIMTA (pemetrexed) and Cisplatin
- Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Mesothelioma
- Phase II trial of perioperative gemcitabine
- Combination Chemotherapy
- Surgery and Photodynamic Therapy
- Cisplatin With or Without Raltitrexed
- Doxorubicin With or Without P-30 Protein
- PTK787/ZK 222584 in Treating Patients
- Erlotinib in Treating Patients
- Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma
- Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma
- Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer
- Experimental Drug SS1(dsFv)-PE38 to Treat Cancer
- Decitabine/Depsipeptide Infusion in Patients with Pulmonary and Pleural Malignancies
- Study of Decitabine in Preventing Tumor Growth
- Treatment of Peritoneal Cancer with Surgery, Perfused Heated Cisplatin, and Chemotherapy
- Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
- Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
- Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
- Study of Anti-Mesothelin Immunotoxin in Advanced Malignancies
- Phase I Study of Erlotinib in Patients With Solid Tumors and Hepatic or Renal Dysfunction
- Phase I Study of Patients With Advanced or Recurrent Malignancy
- Phase I Study of Immunotoxin in Patients
- Phase II Pilot Study of Cyclophosphamide and Active Intralymphatic Immunotherapy
- Phase II Pilot Study of Surgery and Adjuvant Intracavitary Photodynamic Therapy
- Phase II Randomized Study of Gemcitabine and Cisplatin With Malignant Mesothelioma
- Phase II Study of Antineoplastons in Patients with Stage IV Mesothelioma
- Phase II Study of Patients With Malignant Pleural Mesothelioma
- Phase II Study of Gemcitabine
